PE20030865A1 - PHARMACEUTICAL COMPOSITIONS FOR VIRAL PROTEASE INHIBITORS OF HEPATITIS C - Google Patents

PHARMACEUTICAL COMPOSITIONS FOR VIRAL PROTEASE INHIBITORS OF HEPATITIS C

Info

Publication number
PE20030865A1
PE20030865A1 PE2003000135A PE2003000135A PE20030865A1 PE 20030865 A1 PE20030865 A1 PE 20030865A1 PE 2003000135 A PE2003000135 A PE 2003000135A PE 2003000135 A PE2003000135 A PE 2003000135A PE 20030865 A1 PE20030865 A1 PE 20030865A1
Authority
PE
Peru
Prior art keywords
composition
cycloalkyl
hepatitis
hilo
alkyl
Prior art date
Application number
PE2003000135A
Other languages
Spanish (es)
Inventor
Xiaohui Mei
Shirlynn Chen
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of PE20030865A1 publication Critical patent/PE20030865A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA PARA INHHIBIR EL VIRUS DE LA HEPATITIS C CON UNA BIODISPONIBILIDAD MEJORADA QUE COMPRENDE a)DE 1% A 50% DE COMPUESTOS MACROCICLICOS INHIBIDORES DE PROTEASA NS3 VIRAL DE FORMULA I, DONDE: R1 ES H, HALO, ALQUILO, CICLOALQUILO, HALOALQUILO, ALCOXI, CICLOALCOXI, ENTRE OTROS; R2 ES H, HALO, ALQUILO, CICLOALQUILO, ENTRE OTROS; R3 ES R9O, R9NH; R9 ES ALQUILO, CICLOALQUILO; R4 ES H; b) DE 0,1% A 7% DE UNA AMINA TAL COMO ETANOLAMINA, ETILENDIAMINA, TRIS(HIDROXIMETIL)AMINOMETANO; c)ACEITES (TRIGLICERIDOS, VITAMINAS, ACIDOS GRASOS), VEHICULO (POLIMERO, UREA), DISOLVENTES HIDROFILOS (PROPILENGLICOL, ETANOL, AGUA); SI c) ES ACEITE, LA COMPOSICION COMPRENDE ADEMAS d)DISOLVENTES e)HASTA 50% EN PESO DE POLIMEROS COMO POLIETILENGLICOL, POLIVINILPIRROLIDONA, DERIVADOS DE CELULOSA; f)HASTA 70% EN PESO DE TENSIOACTIVOS COMO SUCCINATO DE D-ALFA-TOCOFEROL-POLIETILENGLICOL 1000, ACEITE DE RICINO; SI c) ES UN VEHICULO, LA COMPOSICION COMPRENDE TENSIOACTIVOS. LA COMPOSICION PUEDE COMPRENDER ADEMAS DE 0,01% A 1% DE ANTIOXIDANTES. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACIONREFERS TO A PHARMACEUTICAL COMPOSITION TO INHIBIT THE HEPATITIS C VIRUS WITH ENHANCED BIODAVAILABILITY THAT INCLUDES a) FROM 1% TO 50% OF INHIBITING MACROCYCLIC COMPOUNDS OF PROTEASE NS3 VIRAL FORMULA I, WHERE HILO: R1, IS HILO: R1 CYCLOALKYL, HALOALKYL, ALCOXI, CYCLOALCOXI, AMONG OTHERS; R2 IS H, HALO, ALKYL, CYCLOALKYL, AMONG OTHERS; R3 IS R9O, R9NH; R9 IS ALKYL, CYCLOALKYL; R4 IS H; b) FROM 0.1% TO 7% OF AN AMINE SUCH AS ETHANOLAMINE, ETHYLENEDIAMINE, TRIS (HYDROXIMETHYL) AMINOMETHANE; c) OILS (TRIGLYCERIDES, VITAMINS, FATTY ACIDS), VEHICLE (POLYMER, UREA), HYDROPHILIC SOLVENTS (PROPYLENE GLYCOL, ETHANOL, WATER); IF c) IT IS OIL, THE COMPOSITION ALSO INCLUDES d) SOLVENTS e) UP TO 50% BY WEIGHT OF POLYMERS SUCH AS POLYETHYLENE GLYCOL, POLYVINYLPYRROLIDONE, CELLULOSE DERIVATIVES; f) UP TO 70% BY WEIGHT OF SURFACTANTS SUCH AS D-ALPHA-TOCOPHEROL-POLYETHYLENGLYCOL 1000 SUCCINATE, RICINO OIL; IF c) IT IS A VEHICLE, THE COMPOSITION INCLUDES TENSIOACTIVES. THE COMPOSITION MAY INCLUDE IN ADDITION FROM 0.01% TO 1% OF ANTIOXIDANTS. ALSO REFERS TO A PROCEDURE FOR THE PREPARATION

PE2003000135A 2002-02-07 2003-02-05 PHARMACEUTICAL COMPOSITIONS FOR VIRAL PROTEASE INHIBITORS OF HEPATITIS C PE20030865A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35569402P 2002-02-07 2002-02-07

Publications (1)

Publication Number Publication Date
PE20030865A1 true PE20030865A1 (en) 2003-11-26

Family

ID=27734548

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000135A PE20030865A1 (en) 2002-02-07 2003-02-05 PHARMACEUTICAL COMPOSITIONS FOR VIRAL PROTEASE INHIBITORS OF HEPATITIS C

Country Status (25)

Country Link
US (1) US6828301B2 (en)
EP (1) EP1474172B1 (en)
JP (1) JP2005518423A (en)
KR (1) KR20040089605A (en)
CN (1) CN1627959A (en)
AR (1) AR038823A1 (en)
AT (1) ATE344056T1 (en)
AU (1) AU2003208989A1 (en)
BR (1) BR0307524A (en)
CA (1) CA2472249A1 (en)
CO (1) CO5611167A2 (en)
DE (1) DE60309433T2 (en)
EA (1) EA200400991A1 (en)
EC (1) ECSP045223A (en)
ES (1) ES2276045T3 (en)
HR (1) HRP20040720A2 (en)
IL (1) IL162673A0 (en)
MX (1) MXPA04007699A (en)
NO (1) NO20043722L (en)
PE (1) PE20030865A1 (en)
PL (1) PL371287A1 (en)
TW (1) TW200302734A (en)
UY (1) UY27650A1 (en)
WO (1) WO2003066103A1 (en)
ZA (1) ZA200405064B (en)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3889708B2 (en) 2000-11-20 2007-03-07 ブリストル−マイヤーズ スクイブ カンパニー Hepatitis C tripeptide inhibitor
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
DE60334205D1 (en) 2002-05-20 2010-10-28 Bristol Myers Squibb Co Heterocyclische sulfonamid-hepatitis-c-virus-hemmer
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
JP4271148B2 (en) 2002-05-20 2009-06-03 ブリストル−マイヤーズ スクイブ カンパニー Substituted cycloalkyl P1 'hepatitis C virus inhibitors
PL215228B1 (en) 2002-05-20 2013-11-29 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US20040033959A1 (en) * 2002-07-19 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical compositions for hepatitis C viral protease inhibitors
US20040138109A1 (en) * 2002-09-30 2004-07-15 Boehringer Ingelheim Pharmaceuticals, Inc. Potent inhibitor of HCV serine protease
US20050159345A1 (en) * 2002-10-29 2005-07-21 Boehringer Ingelheim International Gmbh Composition for the treatment of infection by Flaviviridae viruses
WO2004050068A1 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
UY28240A1 (en) * 2003-03-27 2004-11-08 Boehringer Ingelheim Pharma CRYSTAL PHASES OF A POWERFUL HCV INHIBITOR
WO2004093915A1 (en) * 2003-04-02 2004-11-04 Boehringer Ingelheim International, Gmbh Pharmaceutical compositions for hepatitis c viral protease inhibitors
US7176208B2 (en) * 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
JP4704342B2 (en) * 2003-09-22 2011-06-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Macrocyclic peptide active against hepatitis C virus
CN103145715B (en) * 2003-10-14 2016-08-03 F·霍夫曼-罗须公司 Huge ring carboxylic acid and acyl sulfonamides as HCV replication inhibitors
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2539575C (en) 2003-11-20 2015-01-20 Boehringer Ingelheim International Gmbh Method of removing transition metals, especially from metathesis reaction products
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
JP4682155B2 (en) * 2004-01-21 2011-05-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Macrocyclic peptide active against hepatitis C virus
WO2005073195A2 (en) 2004-01-30 2005-08-11 Medivir Ab Hcv ns-3 serine protease inhibitors
WO2005095403A2 (en) * 2004-03-30 2005-10-13 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
WO2005123076A2 (en) * 2004-06-08 2005-12-29 Vertex Pharmaceuticals, Inc. Pharmaceutical compositions
PL1778702T3 (en) * 2004-07-16 2011-12-30 Gilead Sciences Inc Antiviral compounds
WO2007001406A2 (en) * 2004-10-05 2007-01-04 Chiron Corporation Aryl-containing macrocyclic compounds
US20070249637A1 (en) * 2004-10-21 2007-10-25 Collins Michael R Inhibitors Of Hepatitis C Virus Protease, And Compositions And Treatments Using The Same
US20060088591A1 (en) * 2004-10-22 2006-04-27 Jinghua Yuan Tablets from a poorly compressible substance
AU2005302501A1 (en) * 2004-10-29 2006-05-11 Novartis Ag Spontaneously dispersible pharmaceutical compositions
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20060240051A1 (en) * 2005-04-26 2006-10-26 Singleton Andy H Eutectic blends containing a water soluble vitamin derivative
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PE20070011A1 (en) * 2005-06-02 2007-03-08 Schering Corp PHARMACEUTICAL FORMULATIONS OF HCV PROTEASE INHIBITOR COMPOUNDS OR CATEPSIN
EP1891089B1 (en) 2005-06-02 2014-11-05 Merck Sharp & Dohme Corp. HCV protease inhibitors in combination with food
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI387603B (en) 2005-07-20 2013-03-01 Merck Sharp & Dohme Hcv ns3 protease inhibitors
EP2305697A3 (en) 2005-07-25 2011-07-27 Intermune, Inc. Macrocyclic inhibitors of Hepatitis C virus replication
PE20070211A1 (en) 2005-07-29 2007-05-12 Medivir Ab MACROCYCLIC COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS
US20090068253A1 (en) * 2005-09-06 2009-03-12 Guilford F Timothy Method for the treatment of infection with hhv-6 virus and the amelioration of symptoms related to virus using liposomal encapsulation for delivery of reduced glutathione
DE602006019323D1 (en) 2005-10-11 2011-02-10 Intermune Inc COMPOUNDS AND METHOD FOR INHIBITING THE REPLICATION OF THE HEPATITIS C VIRUS
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR20090024834A (en) 2006-07-05 2009-03-09 인터뮨, 인크. Novel inhibitors of hepatitis c virus replication
EP2043658B1 (en) * 2006-07-07 2012-04-25 Gilead Sciences, Inc. Antiviral phosphinate compounds
US7935670B2 (en) 2006-07-11 2011-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2008251425A1 (en) 2007-05-10 2008-11-20 Array Biopharma, Inc. Novel peptide inhibitors of hepatitis C virus replication
AP2874A (en) 2007-06-29 2014-03-31 Gilead Sciences Inc Antiviral compounds
AU2008271117B2 (en) 2007-06-29 2013-10-24 Gilead Sciences, Inc. Antiviral compounds
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
EP2250174B1 (en) 2008-02-04 2013-08-28 IDENIX Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
JP2011519364A (en) 2008-04-15 2011-07-07 インターミューン・インコーポレーテッド Novel macrocyclic inhibitor of hepatitis C virus replication
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2300491B1 (en) 2008-05-29 2016-01-06 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (en) 2008-09-11 2010-04-30 Enanta Pharm Inc HEPATITIS C SERINA PROTEASAS MACROCYCLIC INHIBITORS
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN101744823B (en) * 2008-12-17 2013-06-19 广东东阳光药业有限公司 Solid dispersion of dihydropyrimidine compounds and preparation thereof for medical purpose
AR075584A1 (en) 2009-02-27 2011-04-20 Intermune Inc THERAPEUTIC COMPOSITIONS THAT INCLUDE beta-D-2'-DESOXI-2'-FLUORO-2'-C-METHYLYCTIDINE AND A CARDIEX ISOINDOL ACID DERIVATIVE AND ITS USES. COMPOUND.
WO2010118078A1 (en) 2009-04-08 2010-10-14 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
MA33491B1 (en) * 2009-07-07 2012-08-01 Boehringer Ingelheim Int Pharmaceutical formulations of hepatitis c virus enzyme inhibitor
TW201117812A (en) 2009-08-05 2011-06-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
RU2554087C2 (en) 2009-12-18 2015-06-27 Айденикс Фармасьютикалз, Инк. 5,5-condensed arylene or heteroarylene hepatitis c virus inhibitors
KR101579079B1 (en) * 2010-03-10 2015-12-21 애브비 바하마스 리미티드 Solid compositions
EP2640872B1 (en) 2010-11-18 2019-03-13 Metalysis Limited Electrolysis apparatus
KR20140003521A (en) 2010-12-30 2014-01-09 이난타 파마슈티칼스, 인코포레이티드 Phenanthridine macrocyclic hepatitis c serine protease inhibitors
EP2658859A4 (en) 2010-12-30 2014-07-30 Enanta Pharm Inc Macrocyclic hepatitis c serine protease inhibitors
AR085352A1 (en) 2011-02-10 2013-09-25 Idenix Pharmaceuticals Inc MACROCICLIC INHIBITORS OF SERINA PROTEASA, ITS PHARMACEUTICAL COMPOSITIONS AND ITS USE TO TREAT HCV INFECTIONS
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US8957203B2 (en) * 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US20130302414A1 (en) * 2012-05-07 2013-11-14 Bristol-Myers Squibb Company Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
AU2012392557B2 (en) 2012-10-19 2017-06-01 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070974A1 (en) 2012-11-05 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
CN105164148A (en) 2013-03-07 2015-12-16 百时美施贵宝公司 Hepatitis c virus inhibitors
EP3046924A1 (en) 2013-09-20 2016-07-27 IDENIX Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
EP2899207A1 (en) 2014-01-28 2015-07-29 Amikana.Biologics New method for testing HCV protease inhibition
US20170135990A1 (en) 2014-03-05 2017-05-18 Idenix Pharmaceuticals Llc Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
WO2015134560A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Solid forms of a flaviviridae virus inhibitor compound and salts thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE445174B (en) 1978-03-07 1986-06-09 Sandoz Ag PHARMACEUTICAL COMPOSITION CONTAINING A CYCLOSPORIN AND A HEALING SUBSTANCE
US5071643A (en) 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
US5342625A (en) 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
IL102236A0 (en) 1991-06-27 1993-01-14 Ltt Inst Co Ltd Topical preparations containing cyclosporin
GB9208712D0 (en) 1992-04-22 1992-06-10 Sandoz Ltd Pharmaceutical compositions containing cyclosporin derivates
US5376688A (en) 1992-12-18 1994-12-27 R. P. Scherer Corporation Enhanced solubility pharmaceutical solutions
CA2221145A1 (en) 1995-05-19 1996-11-21 Abbott Laboratories Self-emulsifying formulations of lipophilic drugs
BR9810866B1 (en) 1997-07-29 2010-07-13 pharmaceutical composition in a self-emulsifying formulation form for lipophilic compounds.
RU2202346C2 (en) 1997-07-29 2003-04-20 Фармация Энд Апджон Компани Pharmaceutical composition for acid lipophilic compounds in form of self-emulsifying composition
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition

Also Published As

Publication number Publication date
WO2003066103A1 (en) 2003-08-14
CN1627959A (en) 2005-06-15
ZA200405064B (en) 2005-05-30
AU2003208989A1 (en) 2003-09-02
EA200400991A1 (en) 2005-02-24
JP2005518423A (en) 2005-06-23
EP1474172A1 (en) 2004-11-10
PL371287A1 (en) 2005-06-13
US6828301B2 (en) 2004-12-07
EP1474172B1 (en) 2006-11-02
NO20043722L (en) 2004-09-06
DE60309433D1 (en) 2006-12-14
ES2276045T3 (en) 2007-06-16
UY27650A1 (en) 2003-09-30
AR038823A1 (en) 2005-01-26
BR0307524A (en) 2004-12-21
HRP20040720A2 (en) 2005-04-30
TW200302734A (en) 2003-08-16
DE60309433T2 (en) 2007-05-03
ECSP045223A (en) 2004-09-28
KR20040089605A (en) 2004-10-21
MXPA04007699A (en) 2004-11-10
CO5611167A2 (en) 2006-02-28
ATE344056T1 (en) 2006-11-15
IL162673A0 (en) 2005-11-20
CA2472249A1 (en) 2003-08-14
US20030195228A1 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
PE20030865A1 (en) PHARMACEUTICAL COMPOSITIONS FOR VIRAL PROTEASE INHIBITORS OF HEPATITIS C
AR047076A1 (en) PIRROLOTRIAZINE COMPOUNDS AS THYROSINE KINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS
AR074391A1 (en) PHARMACEUTICAL COMPOSITION OF A POWERFUL HCV INHIBITOR FOR ORAL ADMINISTRATION
AR056873A1 (en) DERIVATIVES OF PIRAZOLOPIRIMIDINAS AS QUINASA INHIBITORS OF CYCLINE DEPENDENTS, PHARMACEUTICAL COMPOSITIONS
CO5700671A2 (en) TOPICAL FORMULATIONS THAT INCLUDE A DERIVATIVE OF 1-N-ARILPIRAZOL AND A FORMAMIDINE
AR026102A1 (en) A PROCESS TO STABILIZE A POLYETHYLENE MOCROLLIDE, A SOLID FORM MIX, A PHARMACEUTICAL COMPOSITION, A RAPAMYCIN DERIVATIVE AND A PROCESS TO PURIFY
AR073760A1 (en) HETEROCICLIC DERIVATIVES AND METHODS OF USE OF THE SAME
PA8495101A1 (en) DERIVATIVES OF 13-METHYLERITROMYCIN
DE602004031258D1 (en) POLYCYCLIC AGENT FOR THE TREATMENT OF INFECTIONS
AR042397A1 (en) USEFUL PIRAZOL COMPOUNDS AS PROTEINQUINASE INHIBITORS
PE20091575A1 (en) BIPHENYL DERIVATIVES AS INHIBITORS OF HEPATITIS C VIRUS
AR055041A1 (en) TIADIAZOLS AND OXADIAZOLS AS INHIBITORS OF THE SYNTHESIS OF LEUCOTRIENOS. PHARMACEUTICAL COMPOSITIONS.
MX2008001394A (en) Macrocyclic inhibitors of hepatitis c virus.
GT200600134A (en) NEW COMPOUNDS OF AMINOSULPHONYL DERIVATIVES
UY30493A1 (en) 5-CHLORO-1 ?? H, 3H-ESPIRO [1-BENZOFURAN-2, 4 ?? - PIPERIDIN] -1 ?? - ILO SUBSTITUTES OF ACETIC AND 2-METHYL-PROPANIC ACIDS, PHARMACEUTICAL COMPOSITIONS, PROCEDURES OF PREPARATION AND APPLICATIONS
CO5560559A2 (en) FORMULATION OF STABILIZED ORAL SUSPENSION
RS49850B (en) 1 ,4-BENZOTHIAZEPINE-l, l-DIOXIDE DERIVATIVES SUBSTITUTED BY SUGAR RADICALS, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING THESE COMPOUNDS AND THE USE THEREOF
CL2004000076A1 (en) COMPOUNDS DERIVED FROM INDOL, POLYMERASE INHIBITORS, SALTS; PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM; PROCEDURE FOR PREPARATION OF SUCH COMPOUNDS; INTERMEDIARY COMPOUNDS; AND USE OF THE COMPOUND TO TREAT AN INFECTION CAUSED BY THE VI
SV1998000008A (en) SULFAMIDE-METALOPROTEASE INHIBITORS. REF. RAN 4070 \ 114
AR049274A1 (en) ACID2 - {[2- (2-METHYLAMINOPIRIMIDIN-4-IL) -1H-INDOL-5-CARBONYL] AMINO} -3- (PHENYLPIRIDIN-2-ILAMINO) SUBSTANTIALLY PURE PROPIONIC AS A SELECTIVE KINASE IKK-2 INHIBITOR
AR062797A1 (en) PIPERIDINE DERIVATIVES AS RENINE INHIBITORS, PHARMACEUTICAL COMPOSITIONS.
AR049711A1 (en) HETEROCICLIC COMPOUNDS CONDENSED AS INHIBITORS OF ALDOSTERONE SINTASA; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF DISEASES RELATED TO HYPERALDOSTERISM AND EXCESSIVE CORTISO RELEASE
AR032586A1 (en) PHARMACEUTICAL COMPOSITION
AR054000A1 (en) COMPOSITE OF N- (FENILPROPIL) -SULFONAMIDE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, COMBINATION PRODUCT THAT INCLUDES SUCH COMPOUND AND METHOD TO PREPARE IT
AR047466A1 (en) COMPOUNDS DERIVED FROM 3H - IMIDAZO [4,5 - B] PIRIDINE WITH INHIBITING ACTIVITY OF QUINASA, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AS AN ACTIVE PRINCIPLE AND ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF SUSCEPTIBLE NEOPLASMS.

Legal Events

Date Code Title Description
FD Application declared void or lapsed